Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) have earned a consensus recommendation of “Buy” from the five research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $16.67.
OXFD has been the subject of a number of recent research reports. ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, August 3rd. Finally, BidaskClub lowered shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research note on Friday, July 20th.
Shares of NASDAQ:OXFD traded up $0.24 on Friday, hitting $15.84. 66,112 shares of the company were exchanged, compared to its average volume of 154,625. Oxford Immunotec Global has a one year low of $10.00 and a one year high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.25) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.25). The business had revenue of $29.32 million for the quarter, compared to the consensus estimate of $28.58 million. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.74) EPS.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $139,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 20,000 shares of Oxford Immunotec Global stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $16.71, for a total transaction of $334,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 149,100 shares of company stock worth $2,564,662 over the last ninety days. Insiders own 6.61% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its holdings in Oxford Immunotec Global by 19.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock worth $1,257,000 after acquiring an additional 16,070 shares during the last quarter. Bank of Montreal Can purchased a new position in Oxford Immunotec Global during the 2nd quarter worth $132,000. BlackRock Inc. boosted its holdings in Oxford Immunotec Global by 10.0% during the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock worth $16,490,000 after acquiring an additional 116,814 shares during the last quarter. Spark Investment Management LLC boosted its holdings in shares of Oxford Immunotec Global by 45.1% in the 2nd quarter. Spark Investment Management LLC now owns 144,100 shares of the company’s stock worth $1,857,000 after buying an additional 44,800 shares during the last quarter. Finally, Penn Capital Management Co. Inc. boosted its holdings in shares of Oxford Immunotec Global by 20.4% in the 2nd quarter. Penn Capital Management Co. Inc. now owns 257,026 shares of the company’s stock worth $3,313,000 after buying an additional 43,477 shares during the last quarter. 92.44% of the stock is currently owned by hedge funds and other institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.